PROFESSIONAL EDITION

The largest community of pharma leaders

QIAGEN to Complement COVID-19 Testing Portfolio With Novel Kit That Simplifies and Accelerates PCR Analysis for Research Applications

HILDEN, Germany & GERMANTOWN, Md.–(BUSINESS WIRE)–QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to launch a novel straightforward approach to viral RNA epidemiology that will significantly simplify and accelerate PCR analysis and remove key testing bottlenecks for SARS-CoV-2 and other RNA viruses. QIAGEN’s innovative QIAprep&amp Viral RNA UM Kit combines a liquid-based sample preparation step completed in only two minutes with real-time PCR detection in a stream

Source

Recent Articles